Cetuximab Plus Capecitabine and Irinotecan Compared With Cetuximab Plus Capecitabine and Oxaliplatin As First-Line Treatment for Patients With Metastatic Colorectal Cancer: AIO KRK-0104—A Randomized Trial of the German AIO CRC Study Group (Q43528801)

From Wikidata

Jump to navigation Jump to search

scientific article published on February 7, 2011

Language	Label	Description	Also known as
English	Cetuximab Plus Capecitabine and Irinotecan Compared With Cetuximab Plus Capecitabine and Oxaliplatin As First-Line Treatment for Patients With Metastatic Colorectal Cancer: AIO KRK-0104—A Randomized Trial of the German AIO CRC Study Group	scientific article published on February 7, 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Cetuximab Plus Capecitabine and Irinotecan Compared With Cetuximab Plus Capecitabine and Oxaliplatin As First-Line Treatment for Patients With Metastatic Colorectal Cancer: AIO KRK-0104—A Randomized Trial of the German AIO CRC Study Group (English)

1 reference

10.1200/JCO.2010.31.1936

https://api.crossref.org/works/10.1200/JCO.2010.31.1936

23 November 2024

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Ursula Vehling-Kaiser

3

object named as

Ursula Vehling-Kaiser

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Ludwig Fischer von Weikersthal

2

object named as

Ludwig Fischer von Weikersthal

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

10

object named as

Thomas Decker

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21300933

23 November 2024

Sebastian Stintzing

19

object named as

Sebastian Stintzing

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21300933

23 November 2024

author name string

Nicolas Moosmann

1

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Martina Stauch

4

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Herrmann Dietzfelbinger

6

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Daniel Oruzio

7

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Stefan Klein

8

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Klaus Zellmann

9

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Mathias Schulze

11

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Wolfgang Abenhardt

12

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Gerhard Puchtler

13

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Herbert Kappauf

14

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Johann Mittermüller

15

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Christopher Haberl

16

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Andreas Schalhorn

17

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Andreas Jung

18

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Volker Heinemann

20

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Holger G. Hass

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21300933

23 November 2024

language of work or name

0 references

publication date

7 February 2011

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

full work available at URL

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2010.31.1936?role=tab

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21300933

23 November 2024

http://intl.jco.org/cgi/content/abstract/29/8/1050

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21300933

23 November 2024

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2010.31.1936

1 reference

10.1200/JCO.2010.31.1936

https://api.crossref.org/works/10.1200/JCO.2010.31.1936

23 November 2024

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

29

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

1050-1058

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

1

1 reference

10.1200/JCO.2010.31.1936

https://api.crossref.org/works/10.1200/JCO.2010.31.1936

23 November 2024

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

2

1 reference

10.1200/JCO.2010.31.1936

https://api.crossref.org/works/10.1200/JCO.2010.31.1936

23 November 2024

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

3

1 reference

10.1200/JCO.2010.31.1936

https://api.crossref.org/works/10.1200/JCO.2010.31.1936

23 November 2024

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

4

1 reference

10.1200/JCO.2010.31.1936

https://api.crossref.org/works/10.1200/JCO.2010.31.1936

23 November 2024

Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986.

5

1 reference

10.1200/JCO.2010.31.1936

https://api.crossref.org/works/10.1200/JCO.2010.31.1936

23 November 2024

Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group

6

1 reference

10.1200/JCO.2010.31.1936

https://api.crossref.org/works/10.1200/JCO.2010.31.1936

23 November 2024

Phase III Study of Capecitabine Plus Oxaliplatin Compared With Continuous-Infusion Fluorouracil Plus Oxaliplatin As First-Line Therapy in Metastatic Colorectal Cancer: Final Report of the Spanish Cooperative Group for the Treatment of Digestive Tumor

7

1 reference

10.1200/JCO.2010.31.1936

https://api.crossref.org/works/10.1200/JCO.2010.31.1936

23 November 2024

Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer

8

1 reference

10.1200/JCO.2010.31.1936

https://api.crossref.org/works/10.1200/JCO.2010.31.1936

23 November 2024

Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma

9

1 reference

10.1200/JCO.2010.31.1936

https://api.crossref.org/works/10.1200/JCO.2010.31.1936

23 November 2024

A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer

10

1 reference

10.1200/JCO.2010.31.1936

https://api.crossref.org/works/10.1200/JCO.2010.31.1936

23 November 2024

Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer

11

1 reference

10.1200/JCO.2010.31.1936

https://api.crossref.org/works/10.1200/JCO.2010.31.1936

23 November 2024

Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial

12

1 reference

10.1200/JCO.2010.31.1936

https://api.crossref.org/works/10.1200/JCO.2010.31.1936

23 November 2024

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

13

1 reference

10.1200/JCO.2010.31.1936

https://api.crossref.org/works/10.1200/JCO.2010.31.1936

23 November 2024

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

14

1 reference

10.1200/JCO.2010.31.1936

https://api.crossref.org/works/10.1200/JCO.2010.31.1936

23 November 2024

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

15

1 reference

10.1200/JCO.2010.31.1936

https://api.crossref.org/works/10.1200/JCO.2010.31.1936

23 November 2024

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

16

1 reference

10.1200/JCO.2010.31.1936

https://api.crossref.org/works/10.1200/JCO.2010.31.1936

23 November 2024

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

17

1 reference

10.1200/JCO.2010.31.1936

https://api.crossref.org/works/10.1200/JCO.2010.31.1936

23 November 2024

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

18

1 reference

10.1200/JCO.2010.31.1936

https://api.crossref.org/works/10.1200/JCO.2010.31.1936

23 November 2024

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

19

1 reference

10.1200/JCO.2010.31.1936

https://api.crossref.org/works/10.1200/JCO.2010.31.1936

23 November 2024

A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity

20

1 reference

10.1200/JCO.2010.31.1936

https://api.crossref.org/works/10.1200/JCO.2010.31.1936

23 November 2024

Results of a phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer

21

1 reference

10.1200/JCO.2010.31.1936

https://api.crossref.org/works/10.1200/JCO.2010.31.1936

23 November 2024

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.

22

1 reference

10.1200/JCO.2010.31.1936

https://api.crossref.org/works/10.1200/JCO.2010.31.1936

23 November 2024

Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience

25

1 reference

10.1200/JCO.2010.31.1936

https://api.crossref.org/works/10.1200/JCO.2010.31.1936

23 November 2024

Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.

27

1 reference

10.1200/JCO.2010.31.1936

https://api.crossref.org/works/10.1200/JCO.2010.31.1936

23 November 2024

Identifiers

10.1200/JCO.2010.31.1936

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43528801&oldid=2278855544"